Stellantis Announces Strategic Copper Investment in 28-02-2023, 00:19

Sự kiện ra mắt Tomorrow.City Shanghai 2025, đánh dấu kỷ nguyên mới của đô thị thông minh toàn cầu 15-09-2025, 14:57

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00